Zuckerman Investment Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$219K Hold
5,952
0.02% 126
2025
Q4
$303K Hold
5,952
0.03% 109
2025
Q3
$330K Hold
5,952
0.03% 121
2025
Q2
$411K Sell
5,952
-1,700
-22% -$116K 0.04% 119
2025
Q1
$531K Buy
7,652
+1,700
+29% +$140K 0.06% 109
2024
Q4
$492K Buy
5,952
+6
+0.1% +$649 0.05% 108
2024
Q3
$708K Buy
5,946
+16
+0.3% +$2.13K 0.07% 83
2024
Q2
$846K Hold
5,930
0.1% 77
2024
Q1
$761K Hold
5,930
0.09% 78
2023
Q4
$613K Hold
5,930
0.08% 80
2023
Q3
$539K Buy
5,930
+400
+7% +$35.2K 0.08% 79
2023
Q2
$447K Hold
5,530
0.06% 87
2023
Q1
$440K Hold
5,530
0.07% 82
2022
Q4
$374K Hold
5,530
0.06% 95
2022
Q3
$275K Buy
+5,530
New +$296K 0.05% 99

Other funds holding NVO

Zuckerman Investment Group's NVO Position: Q1 2026 in Review

Zuckerman Investment Group held its Novo Nordisk (NVO) position steady in Q1 2026 at 5,952 shares worth $219K. The position accounts for 0.02% of the portfolio, ranked #126.

Zuckerman Investment Group first reported a position in NVO in Q3 2022 and has held it in 15 quarters since. The position peaked at $846K in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Zuckerman Investment Group held 5,952 shares of Novo Nordisk worth $219K as of Q1 2026.
  • Zuckerman Investment Group left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up 0.02% of Zuckerman Investment Group's portfolio in Q1 2026, its #126 holding.
  • Zuckerman Investment Group first reported a position in Novo Nordisk in Q3 2022 and has held it in 15 quarters since.
  • Zuckerman Investment Group's Novo Nordisk position peaked at $846K in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Zuckerman Investment Group's 13F filing for Q1 2026, filed 15 May 2026.